Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track DERM with free AI briefings, catalyst countdowns, and dilution alerts.

DERM · Journey Medical Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$25.6M Cash on Hand

CF+ Cash Runway

Follow DERM by email Get an email when DERM pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DERM, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jun 2023 · Phase 3 · Results Expected · A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral D
Registry primary completion date, not a results date
Jun 2023 · Phase 3 · Results Expected · A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Tr
Registry primary completion date, not a results date
May 2023 · Phase 1 · Results Expected · Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Ove
Registry primary completion date, not a results date
May 2022 · Phase 1 · Results Expected · A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 m
Registry primary completion date, not a results date
May 2019 · Phase 2 · Results Expected · A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
Registry primary completion date, not a results date
Dec 2016 · Phase 3 · Results Expected · Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Glycopyrronium Topical Wipes	Hyperhidrosis	Phase 3 · NCT02553798	Completed
DFD-29	Papulopustular Rosacea	Phase 3 · NCT05343455	Completed
Glycopyrronium cloth, 2.4%	Palmar Hyperhidrosis	Phase 2 · NCT03880266	Completed
Dose 2 of glycopyrronium, 3.75% QD	Hyperhidrosis	Phase 2 · NCT02129660	Completed
Dose 2 of glycopyrrolate, 3.0% QD	Hyperhidrosis	Phase 2 · NCT02129660	Completed
Dose 1 of glycopyrronium, 2.5% QD	Hyperhidrosis	Phase 2 · NCT02129660	Completed
Dose 1 of glycopyrrolate, 2.0% QD	Hyperhidrosis	Phase 2 · NCT02129660	Completed
Topical Minocycline Foam FXFM244	Confluent and Reticulated Papillomatosis (CARP)	Early Phase 1 · NCT07462702	Not yet recruiting

Also used in these trials (approved or third-party drugs, not DERM's own candidates): Doxycycline, Glycopyrrolate, Minocycline Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

DERM holds $25.6M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DERM files for a raise →

Get the full DERM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DERM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z